US4237165A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of carbohydrate metabolism disorders
Assignee: Science Union et Cie
•
Filing: 1976-06-04
•
Granted: 1980-12-02
•
Expires: 1996-06-04
Abstract
Abstract Pharmaceutical compositions containing a compound selected from 1-(3-trifluoromethyl phenyl)-2-(β-hydroxyethyl)aminopropane and 1-(3-trifluoromethyl phenyl)-2-(β-benzoyloxy ethyl)-aminopropane and physiologically acceptable acid addition salts thereof, useful in the treatment of metabolism disorders.
Inventors
- 👤 Jacques Duhault
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 11:47
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
58 words
A method of treating a human patient in need of a reduction in levels of blood sugar, which consists in administering to said human patient an effective amount therefor of a compound selected from the group consisting of (A) 1-(3-trifluoromethylphenyl)-2-(β-hydroxy-ethyl) amino propane; (B) 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl) amino propane; (C) optical isomers thereof, and (D) physiologically acceptable acid addition salts thereof.
Claim 2
Independent Claim
58 words
A method of treating a human patient in need of a reduction in levels of blood sugar, which consists in administering to said human patient an effective amount therefor of a compound selected from the group consisting of (A) 1-(3-trifluoromethylphenyl)-2-(β-hydroxy-ethyl) amino propane; (B) 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl) amino propane; (C) optical isomers thereof, and (D) physiologically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
25 words
The method as claimed in claim 1, wherein the compound is administered in unit dosage form containing 10 to 300 mg of the active ingredient.
Claim 4
Dependent Claim
23 words
The method of claim 2, wherein the compound is administered in unit dosage form containing 20 to 150 mg of the active ingredient.
Claim 5
Dependent Claim
21 words
The method of claim 1, wherein the compound is 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl) amino propane, optical isomers, or physiologically acceptable acid addition salts thereof.
Claim 6
Dependent Claim
13 words
The method of claim 1, wherein the compound is 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl) amino propane hydrochloride.
Claim 7
Independent Claim
55 words
A method for reducing blood sugar levels and improving tolerance to ingested glucose as indicated by the glucose tolerance test which consists in administering to the patient in need of same an effective amount therefor of a compound selected from the group consisting of 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl)-aminopropane, optical isomers thereof, and physiologically acceptable acid addition salts thereof.
Claim 8
Independent Claim
55 words
A method for reducing blood sugar levels and improving tolerance to ingested glucose as indicated by the glucose tolerance test which consists in administering to the patient in need of same an effective amount therefor of a compound selected from the group consisting of 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl)-aminopropane, optical isomers thereof, and physiologically acceptable acid addition salts thereof.
Claim 9
Dependent Claim
25 words
The method according to claim 6, wherein human patients are treated with an average dosage amounting to 450 mg daily of 1-(3-trifluoromethylphenyl)-2-(β-benzoyloxy-ethyl)-aminopropane acid addition salt.
Claim 10
Dependent Claim
14 words
The method according to claim 7, wherein the acid addition salt is the hydrochloride.
Claim 11
Dependent Claim
25 words
The method according to claim 6, wherein the compound is administered in unit dosage form containing 10 to 300 mg of the essential active ingredient.
Claim 12
Dependent Claim
24 words
The method according to claim 9, wherein the compound is administered in unit dosage form containing 20 to 150 mg of the active ingredient.
References Cited (Backward Citations)
US3607909A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-12-02 | 1984-06-02 | 1984-12-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-12-02 | 1988-06-02 | 1988-12-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-12-02 | 1992-06-02 | 1992-12-02 | $7700.00 | Window Closed / Lapsed |